NEW YORK, July 13, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), an innovative biotechnology company, has qualified to trade on the OTCQX® Best Marketplace.
Amarantus begins trading today on OTCQX under the symbol "AMBS." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Amarantus is developing proprietary treatments for diseases associated with Parkinson's disease, Alzheimer's disease and rare ophthalmological diseases," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "We are thrilled to welcome Amarantus to our family of established, investor-focused OTCQX companies and look forward to helping the company succeed and prosper."
"We are very pleased to have achieved OTC Markets Group's requirements for its premier securities marketplace," said Gerald E. Commissiong, President and CEO of Amarantus. "Trading on the OTCQX is another step toward our goal of a near-term up-listing to a national stock exchange, and will improve the company's ability to attract institutional investors from both inside and outside the United States. This latest corporate milestone should provide additional visibility within the investment community enabling us to build awareness more broadly and expand the current shareholder base in order to drive shareholder value."
Sichenzia Ross Friedman Ference LLP serves as Amarantus' Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF's discovery.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to inform investors of opportunities and risks: the OTCQX® Best Marketplace; the OTCQB® Venture Marketplace; and the OTC Pink® Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
SOURCE OTC Markets Group Inc.